AIM: To systematically evaluate the efficacy and safety of olopatadine combined with pranoprofen in the treatment of allergic conjunctivitis.

METHODS: Using “olopatadine eye drops”, “pranoprofen eye drops” and “allergic conjunctivitis” as keywords, the controlled clinical trials of olopatadine combined with pranoprofen in the treatment of allergic conjunctivitis were searched from Embase, Cochrane library, PubMed, CNKI, Wanfang and VIP database, with an retrieval time from the establishment of the database to January 1, 2022; The Cochrane Risk of Bias Assessment Tool was used to assess the quality of the included studies, and the Egger's test was performed for publication bias of the included literatures. Meta-analysis was performed by using RevMan 5.3.

RESULTS: A total of 24 eligible Chinese literatures were included, with 2 443 patients(2 547 eyes)in total. The test group was administrated olopatadine combined with pranoprofen, and the control group was treated with olopatadine monotherapy; The results of Meta-analysis showed that the clinical efficiency of the test group was better than that of the control group(OR=4.42, 95%CI:3.37-5.80,P<0.00001); There was no significant difference in the incidence of adverse reactions between the test group and the control group(OR=0.89, 95%CI: 0.45-1.75, P=0.73); Egger's test was conducted on the clinical efficiency and the incidence of adverse reactions, which showed that there was publication bias in the clinical efficiency, but the existed publication bias did not affected results through trim and fill method.

CONCLUSIONS: The combination of olopatadine with pranoprofen may improve the clinical efficacy of allergic conjunctivitis. In the future, multicentered, randomized, double-blind studies can be conducted to improve the strength of the evidence.